TRIAL DETAIL
Cixutumumab and Temsirolimus in Treating Young Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Cixutumumab and Temsirolimus in Treating Young Patients With Solid Tumors That Have Recurred or Not Responded to Treatment |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Suspended |
|||
Phase: |
1 |
Start Date 11/01/2008 |
Age of Trial (yrs) 16.4 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
IGF1R inhibitor + mTOR Inhibitor |
|||
Strategy: |
Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
CDR0000639150, COG-ADVL0813 |
|||
Sponsor: |
Children's Oncology Group
National Cancer Institute (NCI) |
|||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
No prior temsirolimus or monoclonal antibody therapy targeting IGF-1R |
|||
Trial Links |
Trial Results |
Drug Information |
| CCI-779 (temsirolimus) in Wikipedia |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Orange |
CA |
92868 |
USA |
||
Washington |
DC |
20010 |
USA |
||
Minneapolis |
MN |
55455 |
USA |
||
3333 Burnet Ave. |
Cincinnati |
OH |
45229 |
USA |